Fatma Fırat

Dr. Fatma Fırat

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Biotechnic & Histochemistry
Verified
Journal Article
Closed access
FFFatma Fırat
Fatma Fırat
MÖM. Özgül
M. Özgül
EUE. Türköz Uluer
E. Türköz Uluer
SIS. Inan
S. Inan
Cancer is a common cause of death worldwide. Approximately 80% of cancer patients use complementary or alternative medicines for treatment. Caffeic acid phenethyl ester (CAPE), the main active component of propolis, exhibits cytotoxic, antiproliferative and anti-cancer effects. Despite its anticancer effects CAPE exhibits no known harmful effects toward normal cells. We investigated the effects of CAPE on angiogenesis, apoptosis and oxidative stress using MDA MB-231, N2a and COLO 320 cell lines and CAPE treatments at 24 and 48 h. A two dimensional cell culture system was used and the findings were evaluated by an indirect immunohistochemical method and H-scores were calculated. CAPE was effective for all three cancer cell lines. After 24 and 48 h, we found a significant decrease in live cells and increased stress in the cells based on e-NOS and i-NOS levels.

10 May 2023 in Annals of Medicine
Verified
Journal Article
Open access
AGAbdullah Gürel
Abdullah Gürel
GGGulhan Gurel
Gulhan Gurel
FFFatma Fırat
Fatma Fırat
EÖEsra Özgül
Esra Özgül
ITIrem Nur Durusu Turkoglu
Irem Nur Durusu Turkoglu
BBBurhan Baylan
Burhan Baylan
Vitamin A has multiple functions in the human body, being involved in growth, epithelial differentiation, vision, immune function and reproduction. While normal spermatogenesis is influenced by sev...

10 August 2022 in Birth Defects Research
Verified
Journal Article
Closed access
ABAbdülkadir BİLİR
Abdülkadir BİLİR
EAEmre Atay
Emre Atay
FFFatma Fırat
Fatma Fırat
YKYunus Emre Kundakci
Yunus Emre Kundakci

Verified
Journal Article
Open access
PDF file
JJale Akgöl
Jale Akgöl
ÖKÖzden Kutlay
Özden Kutlay
AAArzu Keskin Aktan
Arzu Keskin Aktan
FFFatma Fırat
Fatma Fırat
Modified citrus pectin (MCP) modulates galectin-3, a key player in neuroinflammation linked to Alzheimer’s disease. By inhibiting galectin-3, MCP reduces the brain’s inflammatory response and may alleviate cognitive decline. This study examines MCP’s impact on neuroinflammation, cognitive function, and its role in galectin-3 inhibition in a dementia model. Male Wistar rats were assigned to four groups: control (n = 6), scopolamine (SCP) (n = 7), SCP + MCP (n = 7), and MCP only (n = 7). MCP was administered orally at 100 mg/kg/day via drinking water for six weeks. SCP was injected intraperitoneally at 1 mg/kg for seven days to induce an Alzheimer’s-type dementia model. The researchers assessed cognitive performance through the Morris Water Maze (MWM) test. After behavioral tests, blood and brain tissues, including the hippocampus, were collected and stored at −80 °C for analysis. Immunohistochemistry was used to evaluate superoxide dismutase (SOD) activity, malondialdehyde (MDA) levels, brain-derived neurotrophic factor (BDNF), and inflammatory markers (IL-1β, IL-6, TNF-α, and galectin-3). The data were analyzed with SPSS 22. SCP treatment increased lipid peroxidation (MDA) and elevated inflammatory markers (TNF-α, IL-6, and galectin-3), while reducing BDNF and impairing spatial memory. Co-administering MCP with SCP significantly reduced TNF-α, IL-6, and galectin-3 levels; increased BDNF; and improved memory performance. Although MCP did not lower MDA levels, it boosted SOD activity, suggesting antioxidant effects. Modified citrus pectin (MCP) alleviated cognitive impairments and reduced neuroinflammation in Alzheimer’s-type dementia by inhibiting galectin-3. MCP also exhibited antioxidant potential, underscoring its therapeutic promise for neurodegenerative diseases.


7 November 2023 in Microscopy Research and Technique
Verified
Journal Article
Open access
EBElif Büyükerkmen
Elif Büyükerkmen
EAEmre Atay
Emre Atay
FFFatma Fırat
Fatma Fırat
AYAhmet Yüksek
Ahmet Yüksek
ABAbdülkadir BİLİR
Abdülkadir BİLİR
ASAlperen SARITAS
Alperen SARITAS
Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. The aim of this study is to investigate the teratogenic effects of sugammadex on neural tube and embryonic development in early chick embryos. In this study, 50 0-day fertile specific non-pathogenic (SPF) eggs were used. Fifty eggs were divided into 5 different groups, each consisting of 10 pieces. While no substance was given to the control group at the 28th hour of the study, 4 different doses of sugammadex were administered to the experimental groups, respectively 2, 4, 8, 16 mg/kg. Cranio-caudal lengths of embryos, somite numbers, average number of argyrophilic nucleolar regulatory regions (AgNOR) per nucleus, total AgNOR area/total nuclear area (TAA/NA) ratios, Caspase-3 H-Score results, and presence of neural tube defect were compared among the groups. While the mean cranio-caudal lengths, somite counts, TAA/NA ratios and AgNOR counts of the embryos were found to be statistically significantly lower than the control group, Caspase-3 H-Score mean results were found to be significantly higher (p < .05). In addition, it was observed that there was an increase in neural tube patency and developmental delay. As a result, sugammadex crossing the placenta was revealed to increase the release of proapopitotic molecules and disrupt the developmental stages of embryos. Thus, it was determined that sugammadex in increased developmental delay and incidence of neural tube defects in early chick embryos with increased dose dependent. Despite these results, the effects of sugammadex on fetal development in in vivo and in vitro environments should be studied with further studies.